Valuation dashboard for NewAmsterdam Pharma Company N.V. (NAMS) with P/E N/A, P/B 3.89, EV/EBITDA -7.3 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 92.1%, operating margin -34.3%, net margin -36.4%.
At $19.90 (closing price, November 3, 2026), NAMS has negative trailing earnings (P/E not meaningful) and an ROE of -38.33%. Market capitalisation stands at $2.3B.
Balance sheet quality for NAMS: debt-to-equity ratio of 0.00, current ratio of 9.03 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.89 |
| EV / EBITDA | -7.3 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Company N.V. | $2.3B | 3.89 | -38.3% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $9.2B | 18.49 | -27.1% | |
| VKTX | Viking Therapeutics, Inc. | $3.3B | 5.23 | -117.3% | |
| DNLI | Denali Therapeutics Inc. | $3.1B | 3.96 | -34.0% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.7B | 13.58 | -52.9% | |
| SEPN | Septerna Inc | $2.0B | 5.09 | -6.3% |
Price
| Price | $19.90 (closing price, November 3, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | NL |
Profitability
| Return on Equity | -38.33% |
| Return on Invested Capital | -38.70% |
| Return on Assets | -36.84% |
| Gross Margin | 92.15% |
| Operating Margin | -3,432.20% |
| Net Margin | -3,644.21% |
Related companies: MDGL · VKTX · DNLI · AMLX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of NAMS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks